Abilify Maintena (aripiprazole extended release) / Otsuka, BMS, Lundbeck - LARVOL DELTA

Rapid treatment initiation in patients with schizophrenia: evaluation of the clinical and functional outcomes of the two-injection start regimen of aripiprazole once-monthly. (PubMed, Int J Psychiatry Clin Pract) - "The TIS regimen of AOM 400 mg demonstrated rapid symptomatic and functional improvement with good tolerability. Further large-scale prospective studies are warranted."

Journal • CNS Disorders • Psychiatry • Schizophrenia

The current nursing care of patients diagnosed with dual diagnosis: a comprehensive literature review. (PubMed, BMC Nurs) - "Nursing care of patients diagnosed with dual diagnosis is most effective when integrated, patient-centred, and combining psychosocial with pharmacological approaches. Therapeutic relationships, consumer engagement, and structured planning support recovery. However, documentation gaps, low participation, and poor aftercare remain barriers needing innovation, policy, and research."

Journal • CNS Disorders • Mood Disorders

Cost-Minimization Analysis of Aripiprazole 2-Month Ready-to-Use vs. Other Long-Acting Injectable Antipsychotics: Evidence From Ontario (ISPOR-EU 2025) - "Pharmacokinetic bridging data demonstrates comparable exposure to aripiprazole once-monthly (AOM) with prolonged post dose protection.Objective: To evaluate the economic impact on the Ontario Drug Benefit (ODB) program of funding Ari 2MRTU by comparing annual treatment costs with existing reimbursed LAI antipsychotics for maintenance therapy in adults diagnosed with schizophrenia A cost-minimization model was developed from the ODB perspective over a 1-year time horizon, assuming therapeutic equivalence among comparators...Comparators (AOM, risperidone LAI, paliperidone palmitate once monthly [PP1M], and three-monthly [PP3M]) were evaluated per label dosing... These results demonstrate that Ari 2MRTU may deliver cost savings for maintenance treatment of schizophrenia when compared to other LAIs, and this was acrossdifferent initiation scenarios and care settings"

HEOR • CNS Disorders • Mental Retardation • Psychiatry • Schizophrenia

Pharmacokinetic modeling and simulation of a two-injection start with aripiprazole once-monthly in people living with schizophrenia: a plain language summary. (PubMed, Curr Med Res Opin) - No abstract available

Journal • PK/PD data • CNS Disorders • Psychiatry • Schizophrenia

Efficient HPLC-ELSD analysis of sodium and phosphate in aripiprazole extended-release injectable suspensions using trimodal column technology. (PubMed, RSC Adv) - "The method showed adequate robustness in the studied formulations. This novel application of a trimodal column with HPLC-ELSD offers a powerful alternative to ion chromatography or ICP-MS, providing a simpler and cost-effective approach for inorganic ion analysis in complex pharmaceutical matrices."

Journal

Long-Acting Injectable Antipsychotics in Adolescents: From Current Evidence and Gaps to Clinical Practice. (PubMed, Pharmaceuticals (Basel)) - "The evidence was organized by drug class: risperidone, paliperidone, aripiprazole, and other antipsychotics (olanzapine, haloperidol, first-generation depots)...Aripiprazole LAI showed functional gains, short-term tolerability, and encouraging acceptance in case reports...When SUD co-occurs, LAIs may also help mitigate risks related to misuse/diversion of oral medication, provided that care includes systematic SUD screening and early intervention. Prospective controlled studies are urgently needed to establish long-term efficacy and safety in this vulnerable population."

Journal • Review • Autism Spectrum Disorder • Bipolar Disorder • CNS Disorders • Developmental Disorders • Genetic Disorders • Mental Retardation • Mood Disorders • Psychiatry • Schizophrenia

Treating First-episode Psychosis with a Two-injection Start Regimen of Long-acting Aripiprazole in a Person with HIV. (PubMed, Clin Psychopharmacol Neurosci) - "With a multidisciplinary approach, proper diagnosis and appropriate treatment can reduce morbidity and mortality as well as improve functionality and quality of life. Especially in patients with poor oral medication adherence, the use of the two-injection start regimen of long-acting aripiprazole while considering potential drug-drug interactions and extrapyramidal symptoms may improve treatment compliance and reduce the exacerbation risk of psychotic symptoms caused by medication discontinuation."

Journal • CNS Disorders • Human Immunodeficiency Virus • Infectious Disease • Psychiatry

Aripiprazole Long-acting Injectable Two-injection Start to Manage Supersensitivity Psychosis: A Case Report. (PubMed, Clin Psychopharmacol Neurosci) - "This approach may offer a rapid and effective strategy for stabilizing dopamine receptors in patients with DSP. This case highlights the potential role of aripiprazole LAI in DSP management and symptom improvement in complex clinical presentations."

Journal • CNS Disorders • Movement Disorders • Psychiatry • Schizophrenia

Efficacy of aripiprazole long-acting injection monotherapy in pregnancy-related hypomania: A treatment choice through shared decision-making. (PubMed, PCN Rep) - "SDM, when combined with intensive measurement-based care, may effectively manage acute hypomanic episodes during pregnancy. This case demonstrates that a conservative approach, guided by SDM, can be a viable strategy for managing pregnancy-related hypomania, highlighting the importance of an individualized treatment plan that respects patient values in a clinical setting with limited evidence."

Journal • Monotherapy • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry

Persistent Hiccups Associated With Long-Acting Injectable Aripiprazole in a Man With Schizophrenia. (PubMed, J Clin Psychopharmacol) - No abstract available

Journal • CNS Disorders • Psychiatry • Schizophrenia

Discerning identity: clinical challenges in differentiating gender-themed psychotic symptoms from gender dysphoria- a case report (ECNP 2025) - "Initial treatment included haloperidol (10 mg/day) and risperidone (4 mg/day)...Upon discharge, the patient was prescribed olanzapine 20 mg/day and intramuscular long-acting aripiprazole 400 mg monthly...This diagnostic overlap poses substantial challenges, as clinicians must differentiate between a primary psychotic process with gender-themed delusions and a genuine gender identity disorder coexisting with psychosis. Accurate diagnosis is further complicated by the presence of poor insight, affective instability, and complex auditory hallucinations, all of which may obscure the patient's baseline identity and lived experience."

Case report • Clinical • CNS Disorders • Insomnia • Psychiatry • Psychomotor Agitation • Schizophrenia • Sleep Disorder

Cotard's syndrome in the shadow of nihilistic delusions: a clinical case experience (ECNP 2025) - "He was referred to outpatient psychiatry services and was initiated on Olanzapine 5 mg/day, with initial clinical improvement...Delusions and hallucinations decreased, and long-acting injectable Aripiprazole was planned upon discharge to support treatment adherence...Early identification and prompt treatment with antipsychotics, particularly in patients exhibiting delusions of nonexistence or bodily decay, are essential. Long-acting treatment options should be considered for patients with poor insight or adherence issues."

Clinical • Bipolar Disorder • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry • Schizophrenia

Efficacy and tolerability of Aripiprazole 2-month ready-to-use 960 mg in adults patients with schizophrenia (ECNP 2025) - "- Two-Injection Start: On the day of initiation, administer two separate injections—one injection of Aripiprazole 2-Month Ready-to-Use 960 mg and one injection of Aripiprazole Once-Monthly 400 mg at different sites—along with a single 20 mg oral dose of aripiprazole. The proportion of patients on antipsychotic monotherapy increased from 70% at baseline to 90% at study completion. CONCLUSIONSAripiprazole 2-Month Ready-to-Use 960 mg was found to be effective, safe, and well-tolerated under real-world clinical practice conditions."

Clinical • CNS Disorders • Insomnia • Psychiatry • Schizophrenia • Sleep Disorder

Comparison of functionality in patients treated with aripiprazole lai versus paliperidone LAI (ECNP 2025) - "The results suggest that patients treated with Aripiprazole LAI exhibit better overall functioning, as measured by the PSP Scale, compared to those treated with Paliperidone LAI. This may be due to differences in the side effect profiles of the two medications. Aripiprazole LAI, being a third-generation antipsychotic, may have fewer sedative and metabolic side effects than Paliperidone LAI, a second-generation antipsychotic."

Clinical • CNS Disorders • Psychiatry • Schizophrenia

Generic versus brand name neuroleptic long acting injectables: clinical considerations (ECNP 2025) - "(3) Abilify Maintena generic long acting injectable is not marketed in Canada, as yet...Long acting injectables in a hospital and/or community clinic setting require close pharmacovigilance if switched. Mirror image studies, if switched to a generic long acting injectable, are necessary for assessing long term outcome."

Clinical • CNS Disorders • Psychiatry • Schizophrenia

Clinical effectiveness and safety in psychosis with comorbid pulmonary thromboembolism treated with long-acting injectable Aripiprazole every two months (ECNP 2025) - "A recent meta-analysis concluded that both first- and second-generation antipsychotics significantly increase the risk of VTE and pulmonary embolism (PE), with olanzapine, clozapine, haloperidol, perphenazine, and risperidone showing the highest association [1]...The patient also accepted anticoagulant therapy with dabigatran 150 mg...Conclusions Antipsychotics, particularly olanzapine, may raise the risk of serious thromboembolic events even in young patients without clear risk factors. Aripiprazole, both oral and LAI, is a safe, effective alternative in patients with VTE history, enabling ongoing antipsychotic treatment without compromising vascular safety."

Clinical • CNS Disorders • Psychiatry • Schizophrenia

Management of breakthrough psychosis on antipsychotic maintenance medication in a patient treated with long-acting injectable antipsychotic (ECNP 2025) - "The patient was treated with several oral antipsychotics, including amisulpride, olanzapine and aripiprazole. He began treatment with aripiprazole once-monthly 400 mg (AOM 400) after the last discharge in 2019...Conclusions The BAMM phenomenon has also been reported in relation to other long-acting injectable antipsychotics, such as Risperidone or Paliperidone, however, the available data is limited compared to those for aripiprazole [3,4]. This phenomenon reveals that, in some treatment-adherent patients, psychotic symptoms may resurface, especially in stressful situations. Close monitoring and identification of potential causal factors are key to optimizing long-term treatment outcomes."

Clinical • CNS Disorders • Mood Disorders • Psychiatry • Psychomotor Agitation • Schizophrenia • Substance Abuse

Shifting the paradigm: the use of long-acting atypical antipsychotics in acute care (ECNP 2025) - "There is one study evaluating the use of aripiprazole once-monthly (AOM) versus placebo in acute inpatients [1]. Loading strategies have since been developed for AOM [2], and aripiprazole two-monthly (ATM) with two simultaneous injections and single oral dose, which have been shown to achieve therapeutic plasma levels within 24 hours. The two loading deltoid doses of 150 and 100 mg paliperidone palmitate once-monthly (PP1M) can be completed within 4 days, and oral supplementation is not required [3]... The pharmacokinetics of atypical LAIs and new loading strategies with the rapid achievement of therapeutic plasma levels suggest the potential consideration of earlier initiation in a variety of acute care settings. Further research is recommended to evaluate safe and effective protocols for early initiation of LAIs which may improve the care pathways of hospital and community management of schizophrenia. Guidelines should be developed or updated to incorporate the most..."

CNS Disorders • Psychiatry • Schizophrenia

How to stay in full remission in schizophrenia and bipolar disorder (ECNP 2025) - "This case series examines outcomes in patients treated with LAI aripiprazole in long-term remission. Adjunctive therapies such as clozapine and quetiapine appeared beneficial in treatment-resistant profiles. The outcomes suggest that LAIs can contribute meaningfully to recovery-oriented approaches in patients with complex psychiatric needs."

Clinical • Bipolar Disorder • CNS Disorders • Mental Retardation • Mood Disorders • Psychiatry • Schizophrenia

Systemic inflammation and metabolic effects of oral versus long-acting injectable antipsychotics in schizophrenia: a systematic review protocol and preliminary data (ECNP 2025) - "Some studies comparing oral and LAI formulations of olanzapine found no significant differences in weight, BMI, glucose levels, or lipid profiles. Similarly, pooled analyses of oral versus LAI aripiprazole and paliperidone did not reveal significant differences in BMI or cholesterol...This systematic review aims to clarify whether the route of administration plays an independent role in contributing to metabolic or inflammatory burden in patients with SCH or SSD. Results may support more personalized pharmacological strategies with the focus at reducing long-term physical health risks in this population."

Clinical • Review • CNS Disorders • Psychiatry • Schizophrenia

Efficacy of oral and LAI aripiprazole-vs-paliperidone in patients with early-phase schizophrenia: secondary analysis from a large-scale, open-label, randomized trial (EULAST) (ECNP 2025) - "This direct comparison of aripiprazole and paliperidone in early-phase schizophrenia did not find clinically significant differences between the two on discontinuation, hospitalization, and symptom scores. Aripiprazole may offer advantages for patients with SUDs, warranting further investigation."

Clinical • CNS Disorders • Psychiatry • Schizophrenia

Early-onset tardive akathisia following long-acting aripiprazole treatment: successful management with mirtazapine (ECNP 2025) - "Our patient achieved near-full remission of akathisia only after mirtazapine was increased to 30 mg/day,following nonresponse to propranolol, biperiden, clonazepam, and hydroxyzine. Given the 2.5-month gap since the last injection, the remission may be partly due to LAI cessation rather than solely to mirtazapine, although spontaneous remission of tardive akathisia is rare.Although prior studies support the effectiveness of low-dose mirtazapine (15 mg/day) in treating antipsychotic-induced akathisia, our case suggests that higher doses may be required in tardive or refractory presentations[4].Moreover, our case contributes to the limited but growing literature implicating LAI aripiprazole in severe akathisia, even among patients who previously tolerated the oral form[5]. These findings underscore the importance of recognizing early-onset tardive akathisia and considering mirtazapine dose escalation as a second-line strategy when conventional treatments fail."

CNS Disorders • Movement Disorders • Psychiatry

Use of high doses of second-generation long-acting antipsychotics in patients with resistant schizophrenia. Treatment compliance, effectiveness, and tolerability (ECNP 2025) - "Methods A 72-month observational, mirror-image study of patients with severe (Clinical Global Impression-Severity, CGI-S ≥ 5) resistant schizophrenia receiving treatment with ≥75 mg of risperidone long-acting injectable (RLAI) (N = 60), ≥175 mg of monthly paliperidone palmitate (PP) (N = 60), and ≥600 mg of aripiprazole once-monthly (AOM) (N = 30). These SGA LAI treatments improved treatment adherence and outcomes (hospitalizations, suicide attempts, clinical severity, disability) of the patients, with good tolerability, helping them to achieve clinical stabilization and better functioning. Therefore, we suggest that, in some illness-critical conditions, high doses of SGA LAIs could represent an alternative to clozapine, to date the only therapy for resistant schizophrenia"

Clinical • Compliance • CNS Disorders • Psychiatry • Schizophrenia

Mania following long-acting aripiprazole in a patient with opioid and stimulant use: A case report (ECNP 2025) - "We describe a case in which a manic episode with psychotic features emerged shortly after administration of long-acting aripiprazole in a woman with no documented history of bipolar disorder but recent stimulant use and abrupt methadone cessation...Treatment with haloperidol and carbamazepine was introduced, leading to rapid remission...While long-acting antipsychotic formulations may offer benefits in terms of adherence, their introduction in contexts of neurobiological instability requires particular caution. The observed clinical sequence reinforces the importance of phased pharmacological strategies, ongoing symptom reassessment, and a high degree of diagnostic vigilance."

Case report • Clinical • Addiction (Opioid and Alcohol) • Bipolar Disorder • CNS Disorders • Insomnia • Mood Disorders • Psychiatry • Psychomotor Agitation • Sleep Disorder

Predictive factors for therapeutic change in long-acting injectable antipsychotics: a real-world clinical study (ECNP 2025) - "The data extracted included gender, age, primary diagnosis according to ICD-10, type of initial LAI (aripiprazole, paliperidone, or other), and whether a therapeutic change (switching LAI or discontinuation) was required during the observation period. These results underscore the importance of individualized LAI selection based on diagnostic profile to optimize adherence and minimize the need for subsequent treatment modifications in routine clinical practice. Future prospective studies are warranted to confirm these findings and further refine personalized treatment strategies for this population."

Biomarker • Clinical • Real-world • Real-world evidence • Bipolar Disorder • CNS Disorders • Mental Retardation • Mood Disorders • Psychiatry • Schizophrenia